

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

March 5, 2015

CAPRICOR THERAPEUTICS, INC.

(Exact name of Registrant as Specified in its Charter)

Delaware
(State or other jurisdiction
of incorporation)

001-34058
(Commission
File Number)

88-0363465
(I.R.S. Employer
Identification No.)

8840 Wilshire Blvd., 2nd Floor, Beverly Hills, CA
(Address of principal executive offices)

90211
(Zip Code)

(310) 358-3200

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01. Other Events.

On March 5, 2015, Capricor Therapeutics, Inc. issued a press release announcing its receipt of approval from The Nasdaq Stock Market LLC to have its common stock, par value \$0.001 per share (the "Common Stock"), listed on the NASDAQ Capital Market. The Common Stock is expected to begin trading on the NASDAQ Capital Market on Monday, March 9, 2015, under the symbol "CAPR." The Common Stock will continue to trade on the OTCQB under the symbol "CAPR" until the market closes on Friday, March 6, 2015. A copy of the press release is attached as Exhibit 99.1 hereto.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Press Release issued by Capricor Therapeutics, Inc. on March 5, 2015, announcing the approval to list its Common Stock on the NASDAQ Capital Market.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

CAPRICOR THERAPEUTICS, INC.

Date: March 5, 2015

By: /s/ Linda Marbán, Ph.D.

Linda Marbán, Ph.D.

Chief Executive Officer

Exhibit Index

Exhibit Number	Description
99.1	Press Release issued by Capricor Therapeutics, Inc. on March 5, 2015, announcing the approval to list its Common Stock on the NASDAQ Capital Market.



Capricor Therapeutics Announces Uplisting to NASDAQ Capital Market

NASDAQ trading of "CAPR" to commence on March 9, 2015

LOS ANGELES, March 5, 2015 – [Capricor Therapeutics, Inc.](#) (OTCQB: CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has been approved to begin trading its common stock on the NASDAQ Capital Market. Capricor's common stock will begin trading under the same symbol, CAPR, at the opening of market hours on Monday, March 9, 2015.

"Capricor has made significant progress on its clinical programs and being a NASDAQ-listed company should generate broader awareness of our business while we build shareholder value," said Linda Marbán, Ph.D., Chief Executive Officer of Capricor. "Capricor has pursued the uplisting in order to improve visibility of our shares to investors, enhance trading liquidity of our common stock and broaden our potential institutional shareholder base. We are now better positioned to move forward with the development of our therapies aimed at treating cardiovascular disease."

About Capricor Therapeutics

Capricor Therapeutics, Inc. (CAPR), a publicly traded biotechnology company, is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two leading product candidates: CAP-1002 and Cenderitide. The Company was formed through the November 2013 merger between Capricor, Inc., a privately held company with a mission to improve the treatment of heart disease by commercializing cardiac stem cell therapies for patients, and Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular diseases. For additional information visit www.capricor.com.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the conduct, size, timing and results of discovery efforts and clinical trials; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; future royalty streams, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact our business are set forth in our Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission on March 31, 2014, in our Amendment No. 1 to Registration Statement on Form S-1, as filed with the Securities and Exchange Commission on May 23, 2014, and in our Form 10-Q for the quarter ended September 30, 2014, as filed with the Securities and Exchange Commission on November 14, 2014. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we assume no obligation to update these forward-looking statements.

###

For more information, please contact:

Corporate Contact:

Capricor Therapeutics, Inc.

AJ Bergmann, Vice President of Finance

+1-310-358-3200

abergmann@capricor.com

Media Relations:

Russo Partners

Christopher Hippolyte

+1-646-942-5634

chris.hippolyte@russopartnersllc.com

Tony Russo, Ph.D.

+1-212-845-4251

tony.russo@russopartnersllc.com

Investor Relations:

Russo Partners

Robert Flamm, Ph.D.

+1-212-845-4226

robert.flamm@russopartnersllc.com
